Management of platinum-based chemotherapy-induced acute nausea and vomiting:                 is there a superior serotonin receptor antagonist?

Hamadani, Mehdi; Chaudhary, Lubna N.; Awan, Farrukh T.; Khan, Jawad K.; Kojouri, Kiarash; Ozer, Howard; Tfayli, Arafat

doi:10.1177/1078155207078137

Cited by 25 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, an increased prevalence of nausea and vomiting has been reported in women [6,7]. Reasons for this are uncertain, but palliative chemotherapy regimens used for breast and gynecological cancers, which frequently consist of cyclophosphamide and platinum agents, are highly emetogenic [40,41]. Furthermore, past studies have suggested that women may have an increased predisposition for chemotherapy-related nausea and vomiting compared to men [42][43][44].…”

Section: Discussionmentioning

confidence: 90%

Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer

Cheung

Gagliese

et al. 2010

Support Care Cancer

131

113

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 90%

Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer

Cheung

Gagliese

et al. 2010

Support Care Cancer

131

113

View full text Add to dashboard Cite

show abstract

“…In this study, we did not differentiate the individual first generation 5-HT 3 RAs used, in part, to simplify the study design, and also based on an earlier report of no significant difference between the antiemetic efficacy of dolasetron, granisetron, or ondansetron in controlling CINV in patients on platinum-based chemotherapy regimens [21]. …”

Section: Discussionmentioning

confidence: 99%

Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice

Hatoum

Lin

Buchner

et al. 2011

Support Care Cancer

View full text Add to dashboard Cite

PurposeThe aim of this study was to compare the risk of chemotherapy-induced nausea and vomiting (CINV) events for various 5-HT3 RAs in patients who received moderately (MEC) or highly emetogenic chemotherapy (HEC) by evaluating hospital or emergency department (ED) admissions.MethodsPharMetrics claims database was used to identify patients diagnosed with breast cancer (BC) who were initiated on cyclophosphamide-based adjuvant chemotherapy or with lung cancer (LC) initiated on carboplatin-based or cisplatin-based chemotherapy between 2005 and 2008. Patients were stratified in two groups: those initiated and maintained on palonosetron versus those treated with any other 5-HT3 RA regimens in the 6-month post first chemotherapy. Risk for CINV events, identified by ICD-9-CM for nausea, vomiting, and/or dehydration, were estimated using logistic regressions, controlling for age, gender, comorbidity, and total chemotherapy doses or days.ResultsOf the 4,868 cyclophosphamide-treated BC, 5,414 carboplatin-treated LC, and 1,692 cisplatin-treated LC identified, there were 1,864 BC (38.5%), 1,806 carboplatin-treated LC (33.4%), and 390 cisplatin-treated LC (23.0%) in the palonosetron-only group. Palonosetron-only group had significantly lower probability of CINV events associated with ED/hospital admissions in all three cohorts (3.5% vs. 6.3% in BC, 9.5% vs. 13.8% in carboplatin-treated LC, and 16.4% vs. 22.6% in cisplatin-treated LC, all at p < 0.05). Logistic regressions found palonosetron-only group had significantly lower risk of CINV events (odds ratios = 0.550, 0.653, and 0.689 in BC, carboplatin-treated LC and cisplatin-treated LC, respectively, p < 0.05).ConclusionPatients with lung or breast cancer receiving MEC or HEC had significantly lower risk of CINV events associated with hospital/ED admissions if initiated and maintained on palonosetron relative to patients receiving 5-HT3 RA regimens.

show abstract

“…Nausea and vomiting can adversely affect patients' quality of life and make it difficult for them to perform their activities of daily living (Bloechl-Daum, Deuson, Mavros, Hansen, & Herrstedt, 2006). Uncontrolled CINV can give rise to medical complications, including poor nutrition, dehydration, electrolyte imbalances, and physical and mental deterioration (Hamadani et al, 2007). In some cases, patients may refuse to continue potentially beneficial treatment regimens because of treatment-associated nausea and vomiting (Hamadani et al).…”

Section: Impact and Incidence Of Chemotherapyinduced Nausea And Vomitingmentioning

confidence: 98%

Chemotherapy-Induced Nausea and Vomiting: Challenges and Opportunities for Improved Patient Outcomes

Hawkins

Grunberg²

2009

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

Oncology nurses play a pivotal role in the care of patients receiving chemotherapy and are in a prime position to facilitate better care of patients experiencing chemotherapy-induced nausea and vomiting (CINV). However, to do so, they must be kept well apprised of the most recent guidelines, the latest developments in CINV therapy, and the expanding knowledge of CINV pathophysiology. In April 2008, a roundtable meeting of experts in the field of CINV was convened after a detailed needs assessment revealed a knowledge gap in CINV management on the part of oncology nurses. The review found that many practitioners significantly underestimated the occurrence of CINV (particularly of delayed symptoms), and others failed to implement evidence-based guidelines. Presentations included CINV pathophysiology, the significance of CINV prophylaxis, evidence-based guidelines, current treatment options and future therapies, practical nursing considerations in CINV, and CINV learning gaps among oncology nurses, with the topics then discussed by the panel at large.

show abstract

Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?

Abstract: No significant difference exists in the antiemetic efficacy of the three 5-HT(3) antagonists studied in controlling CINV when administered in combination with dexamethasone. Choicce of antiemetic regimen should therefore be based on drug cost.

Cited by 25 publications

References 19 publications

Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer

Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer

Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice

Chemotherapy-Induced Nausea and Vomiting: Challenges and Opportunities for Improved Patient Outcomes

Contact Info

Product

Resources

About